Pilot trial found CBD was feasible and well-tolerated for behavioral problems in children with intellectual disability | Research

The takeaway

A pilot randomized controlled trial of CBD (up to 20 mg/kg/day) in eight children with intellectual disability and severe behavioral problems found 100% completion, no serious adverse events, and a signal of efficacy favoring CBD over placebo.

Pediatric psychiatrists, disability services providers, families of children with intellectual disability and behavioral challenges

100% completion rate with 0 serious adverse events

What the researchers found

All eight randomized children completed the full 8-week protocol. Protocol adherence was excellent: 100% for visits and medication, 92% for blood tests, 88% for questionnaires. No serious adverse events or dropouts occurred. All parents said they would recommend the study to other families. There was an efficacy signal favoring CBD over placebo.

Why it matters

Children with intellectual disability and severe behavioral problems have few effective treatment options, and existing medications carry significant side effect risks. This pilot demonstrates that a full-scale CBD trial is feasible in this population.

The numbers in context

8 children randomized; 100% visit completion; 100% medication adherence; 92% blood test completion; 88% questionnaire completion; 0 serious adverse events; 0 dropouts; CBD dose up to 20 mg/kg/day (max 500 mg twice daily)

How the study worked

Double-blind, placebo-controlled, parallel-design pilot RCT of 98% CBD oil (Tilray) in children aged 8-16 with intellectual disability and severe behavioral problems. CBD was titrated over 9 days to 20 mg/kg/day (max 500 mg twice daily) for 8 weeks. Feasibility, acceptability, safety, and preliminary efficacy were assessed.

What this study cannot tell us

Very small sample (8 children) designed as feasibility pilot, not powered for efficacy. Short duration (8 weeks). Single-center study. The efficacy signal needs confirmation in a larger trial.

How to read the evidence

Well-designed pilot RCT demonstrating feasibility, but far too small (n=8) to draw efficacy conclusions.

When this study was published

Published in 2021.

The bigger picture

This is one of the first placebo-controlled trials of CBD specifically for behavioral problems in children with intellectual disability. The excellent adherence and safety profile clear the way for larger efficacy trials.

Questions still open

What is the optimal CBD dose for behavioral problems in this population? Would longer treatment duration show sustained or increased benefit? Which behavioral domains respond most to CBD?

Common questions

Was CBD safe for these children?

Yes. No serious adverse events occurred during the 8-week trial. The CBD dose was titrated up to 20 mg/kg/day, and all children completed the full protocol without discontinuation.

Did CBD improve behavior?

There was a signal of efficacy favoring CBD over placebo, but with only 8 participants, the study was designed to test feasibility rather than prove effectiveness. A larger trial is needed to confirm whether CBD meaningfully improves severe behavioral problems.

Read the original research

A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability.

British journal of clinical pharmacology, 87(2), 436-446

View on PubMed ↗Publisher’s paper ↗

Citation

Efron, Daryl; Freeman, Jeremy L; Cranswick, Noel; Payne, Jonathan M; Mulraney, Melissa; Prakash, Chidambaram; Lee, Katherine J; Taylor, Kaitlyn; Williams, Katrina. (2021). A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability.. British journal of clinical pharmacology, 87(2), 436-446. https://doi.org/10.1111/bcp.14399